Safety Evaluation of Anti-Infective Agents

抗感染药物的安全性评价

• 批准号: 8540325
• 负责人: Jon Carl Mirsalis
• 金额: $ 234.2万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2013-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8540325
• 关键词: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Biological Response Modifier Therapy; Chemicals; Communicable Diseases; Contracts; Development; Drug Kinetics; Evaluation; HIV; Health; Laboratory Animals; Mission; Modeling; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Patients; Plasmodium; Safety; Toxic effect; Toxicology; drug candidate; effective therapy; infectious disease treatment; pathogen; preclinical evaluation

The objective of this contract is to support the NIAID in its mission to develop safe and effective therapies for the treatment of infectious diseases caused by Human Immunodeficiency Virus (HIV), Mycobacterium tuberculosis, Plasmodium sp., opportunistic pathogens that infect AIDS patients, and others. The NIAID requires a Safety Evaluation Contract to assess the health and safety potential of new therapies under development by, or with the support of, the Division of AIDS, NIAID. The scope of this effort is to evaluate the toxicity and pharmacokinetics of potential chemical and biological therapies for AIDS and other infectious diseases in various laboratory animal species.

该合同的目的是支持NIAID完成其使命，开发安全有效的治疗方法，用于治疗由人类免疫缺陷病毒（HIV）、结核分枝杆菌、疟原虫、机会致病菌感染艾滋病患者和其他人。NIAID要求签订安全性评估合同，以评估NIAID艾滋病司正在开发或在其支持下开发的新疗法的健康和安全潜力。这项工作的范围是评估潜在的化学和生物疗法的艾滋病和其他传染病在各种实验室动物物种的毒性和药代动力学。